Patients with BRCA1 and BRCA2 gene mutations are at increased risk of developing pancreatic cancer and other gastrointestinal cancers.

- **For patients with a BRCA1 mutation:**
  - Absolute lifetime risk of pancreatic cancer is less than 5 percent.
  - Individuals with a first- or second-degree relative with pancreatic cancer are candidates for pancreatic cancer surveillance at age 50 or 10 years younger than the youngest affected individual in the family. Pancreatic surveillance typically involves an annual magnetic resonance imaging (MRI) examination or endoscopic ultrasound (EUS).
  - We recommend initiating colon cancer screening at age 45, if not already started. Colon cancer screening may consist of a colonoscopy or stool-based tests, at the discretion of the patient and provider.
  - We recommend initiating pancreatic cyst surveillance, regardless of age, if there is a known pancreatic cyst on previous imaging in the setting of a BRCA1 gene mutation. Pancreatic surveillance typically involves a MRI or EUS.
Gastrointestinal Cancer Recommendations (cont.)

- For patients with a BRCA2 mutation:
  - Absolute lifetime risk of pancreatic cancer is 5-10 percent.
  - Individuals with a first- or second-degree relative with pancreatic cancer are candidates for pancreatic cancer surveillance at age 50 or 10 years younger than the youngest affected individual in the family. Pancreatic surveillance typically involves an annual magnetic resonance imaging (MRI) examination or endoscopic ultrasound (EUS).
  - We recommend initiating colon cancer screening at age 45, if not already started. Colon cancer screening may consist of a colonoscopy or stool-based tests, at the discretion of the patient and provider.
  - We recommend initiating pancreatic cancer surveillance, regardless of age, if there is a known pancreatic cyst on previous imaging in the setting of a BRCA2 gene mutation. Pancreatic surveillance typically involves a MRI or EUS.

Mount Sinai’s Comprehensive BRCA Program for men and women who have mutations in the BRCA1 or BRCA2 gene provides expert guidance to ensure that you receive appropriate cancer screenings, monitoring, and treatment, as needed.

For information and appointments, call 877-309-BRCA (2722).

www.mountsinai.org/care/cancer/about/brca-program